Clinical trial · no report yet · Phase 2/Phase 3

HALT trial: what clinicians have said so far

Stereotactic Body Radiotherapy for the Treatment of OPD

NCT03256981 ↗
Active, not recruiting
Institute of Cancer Research, United Kingdom
Deep size, estimated: 301+ verified statements once built

We haven't built an HCP commentary report on HALT (oligoprogressive oncogene-addicted NSCLC; tests a strategy, not a drug) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.

Indexed commentary on HALT so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

Indexed so far
55 posts on X, typically up to 242 once built
8 YouTube videos, typically up to 35 once built
1 podcast episode, typically up to 4 once built
1 video on X, typically up to 4 once built

Indexed todayTypical once built

The trial

ClinicalTrials.gov

Official title: Targeted Therapy With or Without Dose Intensified Radiotherapy for Oligo-progressive Disease in Oncogene-addicted Lung Tumours
Phase: Phase 2/Phase 3
Status: Active, not recruiting
Conditions: NSCLC
Interventions: SBRT; TKI
Arms: SBRT and continued TKI therapy · Experimental
Continued TKI therapy alone · Active comparator
Enrollment: 113
Primary outcomes: Progression free survival
Sponsor: Institute of Cancer Research, United Kingdom
Start: Nov 27, 2017
Primary completion: Jul 17, 2023
Results posted: No
Registry record: NCT03256981 · updated Nov 5, 2026

Publications

linked from the registry

Lee J, Koom WS, Byun HK, Yang G, Kim MS, Park EJ, Ahn JB, Beom SH, Kim HS, Shin SJ, Kim K, Chang JS. Metastasis-Directed Radiotherapy for Oligoprogressive or Oligopersistent Metastatic Colorectal Cancer. Clin Colorectal Cancer. 2022 Jun;21(2):e78-e86. doi: 10.1016/j.clcc.2021.10.009. Epub 2021 Nov 18. PubMed 34903471

Get this report

Deep

Report, built on orderBuilt within 24 hours of confirming your order: $1,950

Order this report

Quoted on an estimate of the verified statements in the commentary we've indexed so far. Final coverage is set when we build it.You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded.We build it within 24 hours of confirming your order. If we can't build it to our standard, you aren't charged.

Request a free preview

Ask us to build this report. Once it's built, its free preview (summary, finding titles and coverage) is published on this page and we email you the link. The full report is sold separately. Use your work email; we'll send a link to confirm it.

For agents: .json · .md

Indexed commentary on HALT so far

Reports on the same drug or indication

The trial

Publications